Direct comparison of in vitro susceptibility of wildtype clinical Pseudomonas aeruginosa isolated from adult patients with cystic fibrosis (CF) to TOBI and BRAMITOB (tobramycin inhalation solutions).
Moore
John E
JE
Maeda
Yasunori
Y
Goldsmith
Colin E
CE
Rendall
Jacqueline C
JC
Elborn
J Stuart
JS
D000280:Administration, Inhalation; D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D003550:Cystic Fibrosis / Q000382:microbiology*; D006801:Humans; D008826:Microbial Sensitivity Tests / Q000379:methods; D011552:Pseudomonas Infections / Q000188:drug therapy*; D011550:Pseudomonas aeruginosa / Q000187:drug effects* / Q000302:isolation & purification; D014031:Tobramycin / Q000008:administration & dosage; D055815:Young Adult
D000900:Anti-Bacterial Agents; D014031:Tobramycin